NASDAQ

Oruka Therapeutics, Inc. (ORKA)

397 Thanks from members

Oruka Therapeutics, Inc. (ORKA) demonstrates exceptionally bullish market sentiment driven by positive clinical trial data, a robust pipeline including lead products ORKA-001 and ORKA-002, strong institutional backing, and an expanding cash runway supporting future BLA filings.

Special Briefing

How to Live for 300 Years: The Longevity Sandbox

Explore plasma cleansing, somatic organ swaps, and BCI.

Explore →